LeHavreV1, Main, Exploration, bibRecord, 000953

Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01)

Identifieur interne : 000953 ( Main/Exploration ); précédent : 000952; suivant : 000954

Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01)

Auteurs : C. Le Péchoux ; A. Laplanche [France] ; C. Faivre-Finn [Royaume-Uni] ; T. Ciuleanu [Roumanie] ; R. Wanders [Pays-Bas] ; D. Lerouge [France] ; R. Keus [Pays-Bas] ; M. Hatton [Royaume-Uni] ; G. M. Videtic [États-Unis] ; S. Senan [Pays-Bas] ; A. Wolfson [États-Unis] ; R. Jones [Royaume-Uni] ; R. Arriagada [Suède] ; E. Quoix [France] ; A. Dunant [France]

Source :

Annals of Oncology [ 0923-7534 ] ; 2010.

RBID : PMC:3082159

Abstract

Background: We recently published the results of the PCI99 randomised trial comparing the effect of a prophylactic cranial irradiation (PCI) at 25 or 36 Gy on the incidence of brain metastases (BM) in 720 patients with limited small-cell lung cancer (SCLC). As concerns about neurotoxicity were a major issue surrounding PCI, we report here midterm and long-term repeated evaluation of neurocognitive functions and quality of life (QoL).

Patients and methods: At predetermined intervals, the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and brain module were used for self-reported patient data, whereas the EORTC–Radiation Therapy Oncology Group Late Effects Normal Tissue–Subjective, Objective, Management, Analytic scale was used for clinicians’ assessment. For each scale, the unfavourable status was analysed with a logistic model including age, grade at baseline, time and PCI dose.

Results: Over the 3 years studied, there was no significant difference between the two groups in any of the 17 selected items assessing QoL and neurological and cognitive functions. We observed in both groups a mild deterioration across time of communication deficit, weakness of legs, intellectual deficit and memory (all P < 0.005).

Conclusion: Patients should be informed of these potential adverse effects, as well as the benefit of PCI on survival and BM. PCI with a total dose of 25 Gy remains the standard of care in limited-stage SCLC.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3082159

DOI: 10.1093/annonc/mdq576
PubMed: 21139020
PubMed Central: 3082159

Affiliations:

France, Pays-Bas, Roumanie, Royaume-Uni, Suède, États-Unis
Angleterre, Grand Manchester, Hollande-Septentrionale, Svealand
Amsterdam, Caen, Manchester, Stockholm, Strasbourg

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01)</title>
<author><name sortKey="Le Pechoux, C" sort="Le Pechoux, C" uniqKey="Le Pechoux C" first="C." last="Le Péchoux">C. Le Péchoux</name>
<affiliation><nlm:aff id="aff1">Radiation Oncology Department</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Laplanche, A" sort="Laplanche, A" uniqKey="Laplanche A" first="A." last="Laplanche">A. Laplanche</name>
<affiliation wicri:level="1"><nlm:aff id="aff2">Biostatistics and Epidemiology Unit, Institut Gustave-Roussy, Villejuif, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Biostatistics and Epidemiology Unit, Institut Gustave-Roussy, Villejuif</wicri:regionArea>
<wicri:noRegion>Villejuif</wicri:noRegion>
<wicri:noRegion>Villejuif</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Faivre Finn, C" sort="Faivre Finn, C" uniqKey="Faivre Finn C" first="C." last="Faivre-Finn">C. Faivre-Finn</name>
<affiliation wicri:level="3"><nlm:aff id="aff3">Department of Clinical Oncology, The Christie, Manchester, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Clinical Oncology, The Christie, Manchester</wicri:regionArea>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ciuleanu, T" sort="Ciuleanu, T" uniqKey="Ciuleanu T" first="T." last="Ciuleanu">T. Ciuleanu</name>
<affiliation wicri:level="1"><nlm:aff id="aff4">Medical Oncology Department, Institutul Oncologic I. Chiricuta, Cluj-Napoca, Romania</nlm:aff>
<country xml:lang="fr">Roumanie</country>
<wicri:regionArea>Medical Oncology Department, Institutul Oncologic I. Chiricuta, Cluj-Napoca</wicri:regionArea>
<wicri:noRegion>Cluj-Napoca</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wanders, R" sort="Wanders, R" uniqKey="Wanders R" first="R." last="Wanders">R. Wanders</name>
<affiliation wicri:level="1"><nlm:aff id="aff5">Radiation Oncology Department, MAASTRO Clinic, Maastricht, The Netherlands</nlm:aff>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Radiation Oncology Department, MAASTRO Clinic, Maastricht</wicri:regionArea>
<wicri:noRegion>Maastricht</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lerouge, D" sort="Lerouge, D" uniqKey="Lerouge D" first="D." last="Lerouge">D. Lerouge</name>
<affiliation wicri:level="1"><nlm:aff id="aff6">Radiation Oncology Department, Centre François Baclesse, Caen, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Radiation Oncology Department, Centre François Baclesse, Caen</wicri:regionArea>
<placeName><settlement type="city">Caen</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Keus, R" sort="Keus, R" uniqKey="Keus R" first="R." last="Keus">R. Keus</name>
<affiliation wicri:level="1"><nlm:aff id="aff7">Radiation Oncology Department, Arnhem's Radiotherapeutisch Instituut, Arnhem, The Netherlands</nlm:aff>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Radiation Oncology Department, Arnhem's Radiotherapeutisch Instituut, Arnhem</wicri:regionArea>
<wicri:noRegion>Arnhem</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hatton, M" sort="Hatton, M" uniqKey="Hatton M" first="M." last="Hatton">M. Hatton</name>
<affiliation wicri:level="1"><nlm:aff id="aff8">Department of Clinical Oncology, Weston Park Hospital, Sheffield, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Clinical Oncology, Weston Park Hospital, Sheffield</wicri:regionArea>
<wicri:noRegion>Sheffield</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Videtic, G M" sort="Videtic, G M" uniqKey="Videtic G" first="G. M." last="Videtic">G. M. Videtic</name>
<affiliation wicri:level="1"><nlm:aff id="aff9">Radiation Oncology Department, Cleveland Clinic Foundation, Cleveland, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Radiation Oncology Department, Cleveland Clinic Foundation, Cleveland</wicri:regionArea>
<wicri:noRegion>Cleveland</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Senan, S" sort="Senan, S" uniqKey="Senan S" first="S." last="Senan">S. Senan</name>
<affiliation wicri:level="3"><nlm:aff id="aff10">Radiation Oncology Department, VU University Medical Centre, Amsterdam, The Netherlands</nlm:aff>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Radiation Oncology Department, VU University Medical Centre, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wolfson, A" sort="Wolfson, A" uniqKey="Wolfson A" first="A." last="Wolfson">A. Wolfson</name>
<affiliation wicri:level="1"><nlm:aff id="aff11">Radiation Oncology Department, University of Miami School of Medicine, Miami, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Radiation Oncology Department, University of Miami School of Medicine, Miami</wicri:regionArea>
<wicri:noRegion>Miami</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jones, R" sort="Jones, R" uniqKey="Jones R" first="R." last="Jones">R. Jones</name>
<affiliation wicri:level="1"><nlm:aff id="aff12">Department of Clinical Oncology, Beatson Oncology Centre, Glasgow, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Clinical Oncology, Beatson Oncology Centre, Glasgow</wicri:regionArea>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Arriagada, R" sort="Arriagada, R" uniqKey="Arriagada R" first="R." last="Arriagada">R. Arriagada</name>
<affiliation wicri:level="3"><nlm:aff id="aff13">Radiation Oncology Department, Karolinska Institutet, Stockholm, Sweden</nlm:aff>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Radiation Oncology Department, Karolinska Institutet, Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Quoix, E" sort="Quoix, E" uniqKey="Quoix E" first="E." last="Quoix">E. Quoix</name>
<affiliation wicri:level="1"><nlm:aff id="aff14">Department of Pneumology, Hôpital Lyautey, Strasbourg, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Pneumology, Hôpital Lyautey, Strasbourg</wicri:regionArea>
<placeName><settlement type="city">Strasbourg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dunant, A" sort="Dunant, A" uniqKey="Dunant A" first="A." last="Dunant">A. Dunant</name>
<affiliation wicri:level="1"><nlm:aff id="aff2">Biostatistics and Epidemiology Unit, Institut Gustave-Roussy, Villejuif, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Biostatistics and Epidemiology Unit, Institut Gustave-Roussy, Villejuif</wicri:regionArea>
<wicri:noRegion>Villejuif</wicri:noRegion>
<wicri:noRegion>Villejuif</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">21139020</idno>
<idno type="pmc">3082159</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3082159</idno>
<idno type="RBID">PMC:3082159</idno>
<idno type="doi">10.1093/annonc/mdq576</idno>
<date when="2010">2010</date>
<idno type="wicri:Area/Pmc/Corpus">000174</idno>
<idno type="wicri:Area/Pmc/Curation">000172</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000109</idno>
<idno type="wicri:Area/Ncbi/Merge">000272</idno>
<idno type="wicri:Area/Ncbi/Curation">000272</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000272</idno>
<idno type="wicri:doubleKey">0923-7534:2010:Le Pechoux C:clinical:neurological:outcome</idno>
<idno type="wicri:Area/Main/Merge">000954</idno>
<idno type="wicri:Area/Main/Curation">000953</idno>
<idno type="wicri:Area/Main/Exploration">000953</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01)</title>
<author><name sortKey="Le Pechoux, C" sort="Le Pechoux, C" uniqKey="Le Pechoux C" first="C." last="Le Péchoux">C. Le Péchoux</name>
<affiliation><nlm:aff id="aff1">Radiation Oncology Department</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Laplanche, A" sort="Laplanche, A" uniqKey="Laplanche A" first="A." last="Laplanche">A. Laplanche</name>
<affiliation wicri:level="1"><nlm:aff id="aff2">Biostatistics and Epidemiology Unit, Institut Gustave-Roussy, Villejuif, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Biostatistics and Epidemiology Unit, Institut Gustave-Roussy, Villejuif</wicri:regionArea>
<wicri:noRegion>Villejuif</wicri:noRegion>
<wicri:noRegion>Villejuif</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Faivre Finn, C" sort="Faivre Finn, C" uniqKey="Faivre Finn C" first="C." last="Faivre-Finn">C. Faivre-Finn</name>
<affiliation wicri:level="3"><nlm:aff id="aff3">Department of Clinical Oncology, The Christie, Manchester, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Clinical Oncology, The Christie, Manchester</wicri:regionArea>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ciuleanu, T" sort="Ciuleanu, T" uniqKey="Ciuleanu T" first="T." last="Ciuleanu">T. Ciuleanu</name>
<affiliation wicri:level="1"><nlm:aff id="aff4">Medical Oncology Department, Institutul Oncologic I. Chiricuta, Cluj-Napoca, Romania</nlm:aff>
<country xml:lang="fr">Roumanie</country>
<wicri:regionArea>Medical Oncology Department, Institutul Oncologic I. Chiricuta, Cluj-Napoca</wicri:regionArea>
<wicri:noRegion>Cluj-Napoca</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wanders, R" sort="Wanders, R" uniqKey="Wanders R" first="R." last="Wanders">R. Wanders</name>
<affiliation wicri:level="1"><nlm:aff id="aff5">Radiation Oncology Department, MAASTRO Clinic, Maastricht, The Netherlands</nlm:aff>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Radiation Oncology Department, MAASTRO Clinic, Maastricht</wicri:regionArea>
<wicri:noRegion>Maastricht</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lerouge, D" sort="Lerouge, D" uniqKey="Lerouge D" first="D." last="Lerouge">D. Lerouge</name>
<affiliation wicri:level="1"><nlm:aff id="aff6">Radiation Oncology Department, Centre François Baclesse, Caen, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Radiation Oncology Department, Centre François Baclesse, Caen</wicri:regionArea>
<placeName><settlement type="city">Caen</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Keus, R" sort="Keus, R" uniqKey="Keus R" first="R." last="Keus">R. Keus</name>
<affiliation wicri:level="1"><nlm:aff id="aff7">Radiation Oncology Department, Arnhem's Radiotherapeutisch Instituut, Arnhem, The Netherlands</nlm:aff>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Radiation Oncology Department, Arnhem's Radiotherapeutisch Instituut, Arnhem</wicri:regionArea>
<wicri:noRegion>Arnhem</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hatton, M" sort="Hatton, M" uniqKey="Hatton M" first="M." last="Hatton">M. Hatton</name>
<affiliation wicri:level="1"><nlm:aff id="aff8">Department of Clinical Oncology, Weston Park Hospital, Sheffield, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Clinical Oncology, Weston Park Hospital, Sheffield</wicri:regionArea>
<wicri:noRegion>Sheffield</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Videtic, G M" sort="Videtic, G M" uniqKey="Videtic G" first="G. M." last="Videtic">G. M. Videtic</name>
<affiliation wicri:level="1"><nlm:aff id="aff9">Radiation Oncology Department, Cleveland Clinic Foundation, Cleveland, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Radiation Oncology Department, Cleveland Clinic Foundation, Cleveland</wicri:regionArea>
<wicri:noRegion>Cleveland</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Senan, S" sort="Senan, S" uniqKey="Senan S" first="S." last="Senan">S. Senan</name>
<affiliation wicri:level="3"><nlm:aff id="aff10">Radiation Oncology Department, VU University Medical Centre, Amsterdam, The Netherlands</nlm:aff>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Radiation Oncology Department, VU University Medical Centre, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wolfson, A" sort="Wolfson, A" uniqKey="Wolfson A" first="A." last="Wolfson">A. Wolfson</name>
<affiliation wicri:level="1"><nlm:aff id="aff11">Radiation Oncology Department, University of Miami School of Medicine, Miami, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Radiation Oncology Department, University of Miami School of Medicine, Miami</wicri:regionArea>
<wicri:noRegion>Miami</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jones, R" sort="Jones, R" uniqKey="Jones R" first="R." last="Jones">R. Jones</name>
<affiliation wicri:level="1"><nlm:aff id="aff12">Department of Clinical Oncology, Beatson Oncology Centre, Glasgow, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Clinical Oncology, Beatson Oncology Centre, Glasgow</wicri:regionArea>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Arriagada, R" sort="Arriagada, R" uniqKey="Arriagada R" first="R." last="Arriagada">R. Arriagada</name>
<affiliation wicri:level="3"><nlm:aff id="aff13">Radiation Oncology Department, Karolinska Institutet, Stockholm, Sweden</nlm:aff>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Radiation Oncology Department, Karolinska Institutet, Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Quoix, E" sort="Quoix, E" uniqKey="Quoix E" first="E." last="Quoix">E. Quoix</name>
<affiliation wicri:level="1"><nlm:aff id="aff14">Department of Pneumology, Hôpital Lyautey, Strasbourg, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Pneumology, Hôpital Lyautey, Strasbourg</wicri:regionArea>
<placeName><settlement type="city">Strasbourg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dunant, A" sort="Dunant, A" uniqKey="Dunant A" first="A." last="Dunant">A. Dunant</name>
<affiliation wicri:level="1"><nlm:aff id="aff2">Biostatistics and Epidemiology Unit, Institut Gustave-Roussy, Villejuif, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Biostatistics and Epidemiology Unit, Institut Gustave-Roussy, Villejuif</wicri:regionArea>
<wicri:noRegion>Villejuif</wicri:noRegion>
<wicri:noRegion>Villejuif</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Annals of Oncology</title>
<idno type="ISSN">0923-7534</idno>
<idno type="eISSN">1569-8041</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><bold>Background:</bold>
 We recently published the results of the PCI99 randomised trial comparing the effect of a prophylactic cranial irradiation (PCI) at 25 or 36 Gy on the incidence of brain metastases (BM) in 720 patients with limited small-cell lung cancer (SCLC). As concerns about neurotoxicity were a major issue surrounding PCI, we report here midterm and long-term repeated evaluation of neurocognitive functions and quality of life (QoL).</p>
<p><bold>Patients and methods:</bold>
 At predetermined intervals, the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and brain module were used for self-reported patient data, whereas the EORTC–Radiation Therapy Oncology Group Late Effects Normal Tissue–Subjective, Objective, Management, Analytic scale was used for clinicians’ assessment. For each scale, the unfavourable status was analysed with a logistic model including age, grade at baseline, time and PCI dose.</p>
<p><bold>Results:</bold>
 Over the 3 years studied, there was no significant difference between the two groups in any of the 17 selected items assessing QoL and neurological and cognitive functions. We observed in both groups a mild deterioration across time of communication deficit, weakness of legs, intellectual deficit and memory (all <italic>P</italic>
 < 0.005).</p>
<p><bold>Conclusion:</bold>
 Patients should be informed of these potential adverse effects, as well as the benefit of PCI on survival and BM. PCI with a total dose of 25 Gy remains the standard of care in limited-stage SCLC.</p>
</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
<li>Pays-Bas</li>
<li>Roumanie</li>
<li>Royaume-Uni</li>
<li>Suède</li>
<li>États-Unis</li>
</country>
<region><li>Angleterre</li>
<li>Grand Manchester</li>
<li>Hollande-Septentrionale</li>
<li>Svealand</li>
</region>
<settlement><li>Amsterdam</li>
<li>Caen</li>
<li>Manchester</li>
<li>Stockholm</li>
<li>Strasbourg</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Le Pechoux, C" sort="Le Pechoux, C" uniqKey="Le Pechoux C" first="C." last="Le Péchoux">C. Le Péchoux</name>
</noCountry>
<country name="France"><noRegion><name sortKey="Laplanche, A" sort="Laplanche, A" uniqKey="Laplanche A" first="A." last="Laplanche">A. Laplanche</name>
</noRegion>
<name sortKey="Dunant, A" sort="Dunant, A" uniqKey="Dunant A" first="A." last="Dunant">A. Dunant</name>
<name sortKey="Lerouge, D" sort="Lerouge, D" uniqKey="Lerouge D" first="D." last="Lerouge">D. Lerouge</name>
<name sortKey="Quoix, E" sort="Quoix, E" uniqKey="Quoix E" first="E." last="Quoix">E. Quoix</name>
</country>
<country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Faivre Finn, C" sort="Faivre Finn, C" uniqKey="Faivre Finn C" first="C." last="Faivre-Finn">C. Faivre-Finn</name>
</region>
<name sortKey="Hatton, M" sort="Hatton, M" uniqKey="Hatton M" first="M." last="Hatton">M. Hatton</name>
<name sortKey="Jones, R" sort="Jones, R" uniqKey="Jones R" first="R." last="Jones">R. Jones</name>
</country>
<country name="Roumanie"><noRegion><name sortKey="Ciuleanu, T" sort="Ciuleanu, T" uniqKey="Ciuleanu T" first="T." last="Ciuleanu">T. Ciuleanu</name>
</noRegion>
</country>
<country name="Pays-Bas"><noRegion><name sortKey="Wanders, R" sort="Wanders, R" uniqKey="Wanders R" first="R." last="Wanders">R. Wanders</name>
</noRegion>
<name sortKey="Keus, R" sort="Keus, R" uniqKey="Keus R" first="R." last="Keus">R. Keus</name>
<name sortKey="Senan, S" sort="Senan, S" uniqKey="Senan S" first="S." last="Senan">S. Senan</name>
</country>
<country name="États-Unis"><noRegion><name sortKey="Videtic, G M" sort="Videtic, G M" uniqKey="Videtic G" first="G. M." last="Videtic">G. M. Videtic</name>
</noRegion>
<name sortKey="Wolfson, A" sort="Wolfson, A" uniqKey="Wolfson A" first="A." last="Wolfson">A. Wolfson</name>
</country>
<country name="Suède"><region name="Svealand"><name sortKey="Arriagada, R" sort="Arriagada, R" uniqKey="Arriagada R" first="R." last="Arriagada">R. Arriagada</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/France/explor/LeHavreV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000953 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000953 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/France
   |area=    LeHavreV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     PMC:3082159
   |texte=   Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01)
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:21139020" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a LeHavreV1

This area was generated with Dilib version V0.6.25.
Data generation: Sat Dec 3 14:37:02 2016. Site generation: Tue Mar 5 08:25:07 2024

Serveur d'exploration sur la visibilité du Havre

Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01)

Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01)

Source :

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration sur la visibilité du Havre
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.